Method for diagnosing cancer using specific PSCA antibodies
US6261791A · kind A · utility
21Cited by
3References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 1999 |
| Grant date | Jul 17, 2001 |
| Priority date | — |
| Expiry date | May 25, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, bladder cancer and bone metastasis of prostate cancer. Antibodies specific to PSCA are used for diagnosis of these cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.